Clinical Trials

DNAtrix’s lead product, DNX-2401, is currently being evaluated in clinical trials as a single agent or together with other therapies.

DNX-2401 is a conditionally-replicative oncolytic adenovirus that has been engineered to specifically target a large number of tumor cell types. Multiple genetic modifications have been made to the virus so that DNX-2401 selectively infects and kills tumor cells while sparing normal healthy cells.

click map

Clinical Trial Clinical Trial